Gut microbiome dysbiosis and inflammatory markers in severe COVID-19: links to atherosclerosis and potential therapeutic insights Authors: Nayebali Ahmadi, Mohammad Javad Hossein Tehrani, Ashkan Alamdary, Rasul Moukhah, Rajab Mardani, Maryam Shahali Published: 2025 ABSTRACT AbstractBackground:COVID-19 is implicated in the exacerbation of atherosclerosis, potentially leading to its clinical manifestations. The aim of this study was to evaluate serum biomarkers, including albumin (ALB), C-reactive protein (CRP), ferritin (FERR), CD16, CD18, NLRP3, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), in patients with COVID-19. In addition, assessment of microbiome profiles may provide insights into disease severity and gastrointestinal health. Method:In this case-control study, serum samples were collected from 90 individuals: 30 patients with COVID-19 admitted to the intensive care unit, 30 hospitalized patients with COVID-19, and 30 healthy individuals. Concentrations of ALB, CRP, FERR, NLRP3, CD16, CD18, IL-6, and TNF-α were measured. Quantitative PCR (qPCR) was used to assess microbial diversity in stool samples. Result:No significant age difference was noted between the patient (55.40 ± 10.34 years) and the control groups (58.34 ± 11.71 years). Substantial increases in CRP, CD-18, CD-16, IL-6, Alb, and TNF-α (P < 0.001) were observed in severe cases compared to non-severe cases. Microbiome analysis indicated a 40% decrease in Roseburia and a 35% reduction in Faecalibacterium in ICU patients. Conclusion:Evaluating these biomarkers provides critical insights into atherosclerosis susceptibility in COVID-19 patients and reveals meaningful relationships among COVID-19, atherosclerosis, and gastrointestinal health.Key Words: COVID-19, Inflammasomes, Gut Microbiome, Atherosclerosis Introduction On December 31, 2019, some instances of excessive respiration contamination were reported in Wuhan, Hubei Province, China. This virus, abbreviated SARS-CoV-2, may have crossed the interspecies barrier, spreading from bats to people (1). Coronaviruses belong to the Coronaviridae family and are high-quality single-stranded RNA viruses surrounded by an envelope. They're divided into four genera: alpha, beta, gamma, and delta coronavirus. So far, seven human coronaviruses (HCoVs) have been identified, which belong to two genera: alpha and betacoronavirus (2). Pneumonia caused by the new coronavirus is highly contagious, and in the last few months the World Health Organization has declared a global public health emergency. In the latest articles, the acute effects of coronavirus sickness that contain exceptional structures inside the body have been stated, some of the most important of which are the presence of SARS-CoV-2 RNA within the heart tissue and the involvement of the cardiovascular system throughout the ailment; however, still there may be no proof of direct cardiotropic cellular enter (3). Theoretically, SARS-CoV-2 infects a wide range of cells, as does SARS-CoV in vitro (4). Based on these facts, it's predicted that both SARS and Coronavirus behave similarly within the body. Atherosclerosis and other cardiovascular disorders are risk factors for the development of COVID-19. On the flip side, COVID-19 can result in cardiovascular disorders. Those consequences encompass myocarditis, myocardial damage, and myocardial infarction (5). Pathological situations affecting the cardiovascular gadget, which might be strongly related to the improvement of atherosclerosis, along with heart failure (HF), coronary artery disorder (CHD), hypertension (HTN), and diabetes mellitus (DM), have been tested to may be taken into consideration as predictive factors for severity and susceptibility at some stage in SARS-CoV-2 contamination (6). Laboratory findings aren't pathognomonic; however, lymphopenia, extended prothrombin time, and lactate dehydrogenase (LDH) are the maximum distinguished, and a few patients with intense pneumonia have multiplied tiers of things inclusive of NLRP3, CRP, and ferritin (7) .it has been established that the level of acute section inflammatory markers such as CRP and ALB increases in patients with higher ranges of troponin. Myocardial harm is regularly determined amongst sufferers of COVID-19, but it's far more commonly marked by a rise in troponin levels (8). CD16 is used as a further marker to identify neutrophils: mature neutrophils are CD16 high, while eosinophils and monocytes are both CD16 low. CD16 allows for distinction between these two types of granulocytes. The Fc receptor CD16 is the only receptor that can activate resting NK cells when stimulated in isolation. CD16 facilitates ADCC, a process that relies on antibodies generated by B cells. Therefore, the unwanted activation of resting NK cells through CD16 is still under the control of B cells and the adaptive immune system (9). Integrin beta-2 (English: Integrin beta-2) or "CD18" is a protein that is coded by the "ITGB2" gene in humans (10). The lack of this protein in humans causes "leukocyte binding deficiency" in which white blood cells can to defend the body, they do not leave the veins and go to the affected tissues, Intercellular Adhesion Molecule 1 or "ICAM-1", also known as "CD54", is a protein encoded by the "ICAM1" gene in humans. This gene encodes a cell-surface glycoprotein expressed on cells of the vascular layer and the immune system. The resulting protein binds to CD11a/CD18 or CD11b/CD18 integrin, and viruses use it as a "receptor" (11). Recent research has increasingly recognized the intricate connection between gastrointestinal health and cardiovascular diseases, including atherosclerosis. Atherosclerosis, characterized by the accumulation of lipid-laden plaques within the arterial walls, can be influenced by various systemic factors, including inflammation and immune responses. Gastrointestinal diseases often lead to dysbiosis, an imbalance in the gut microbiome, which may exacerbate inflammatory processes. In individuals with compromised gastrointestinal health, there is a heightened risk of developing systemic inflammation, which can contribute to the progression of atherosclerosis. The advent of the COVID-19 pandemic has further illuminated these relationships, as patients with COVID-19 frequently display gastrointestinal symptoms alongside respiratory issues. The measured biomarkers (ALB, CRP, FERR, NLRP3, CD16, CD18, IL-6, TNF-α) and gut microbial diversity reflect shared inflammatory and immune signaling across diseases. Key pathways such as NF-κB and IL-6/STAT3 drive cytokine production and innate immune activation, observed in COVID-19, diabetes, and autoimmune conditions. Gut microbiota–derived metabolites influence PRR signaling and NLRP3 inflammasome activation, linking dysbiosis to systemic inflammation in these diseases. This common signaling axis may underlie differences in severity and cross-disease risks. Methods Sample collection and section A total of 90 subjects (48 males, 42 females) were enrolled from Ayatollah Kashani Hospital (Tehran, Iran): 30 ICU patients with COVID-19, 30 inpatients with COVID-19, and 30 controls. All participants had throat swabs collected for SARS-CoV-2 testing, and PCR was performed using the SANSURE Novel Coronavirus Nucleic Acid Diagnostic Kit. To assess the accuracy of the study, the ex-ante power analysis included the following exclusion criteria: age <18 years, immunodeficiency/immunosuppressive therapy, recent use of antibiotics/probiotics, chronic gastrointestinal disease, pregnancy, inability to provide samples, and collection of comorbidities (e.g., diabetes, hypertension, cardiovascular disease, obesity, chronic kidney disease, chronic lung disease). Determination of CRP concentration CRP levels were quantified using a CRP kit (Pars Azmun, Iran). The measurement was based on determining turbidity resulting from the formation of a complex between CRP in the patient's sample and a sensitized antibody against human CRP. The turbidity detected by immunoturbidimetry was directly proportional to the amount of CRP in the sample and was reported in mg/dl. Measurement of ALB concentration ALB level was quantified using an ALB kit (MAN, Iran). The measurement was based on serum albumin, measured colorimetrically using Green Bromocresol at pH 4.2, and reported as g/dL. Measurement of FERR concentration Serum Ferritin level was measured using Dia. Pro ELISA diagnostic kit (Dia. Pro Diagnostic Bioprobes, Milan, Italy) based on the quantitative immunoenzymometry method. The assay was based on specific monoclonal antibodies and the sandwich method. An anti-ferritin monoclonal antibody (Dia. Pro Diagnostic Bioprobes, Milan, ItalyMilan, Italy) was used to conjugate with the HRP enzyme to cover the space between the solid phase and the anti-ferritin antibody. Upon addition of the sample serum, the ferritin molecule reacted with antibodies, forming sandwiches between the bound antibodies on the solid phase and the conjugated antibody. The intensity of the complex was measured at 450 nm, and the results were reported as ng/ml. Measurement of serum NLRP3 level The level of NLRP3 in serum samples was determined using the Abcam Sandwich ELISA Immunoassay kit (Abcam plc, Inc., UK) according to the manufacturer's instructions. Briefly, serum samples were added to wells in microplates that were pre-coated with an anti-NLRP3-specific antibody (Abcam, UK). After incubating the microplates at room temperature for 2 hours, a conjugated secondary antibody (Abcam, UK) was added to the samples to bind the protein of interest. Finally, the optical density was measured at 450 nm, and NLRP3 levels were expressed in ng/mL. Measurement of CD16 and CD18 level The levels of CD16 and CD18 in serum samples were determined using the Abcam Sandwich ELISA Immunoassay kit (Abcam plc, Inc., UK) according to the manufacturer's instructions. This assay employs an antibody specific for Human CD16 and CD18 coated on a 96-well plate. Standards and samples are pipetted into the wells, and Human CD16 and CD18 present in the samples bind to the immobilized antibody. The wells are washed, and biotinylated anti-Human CD16 and CD18 antibody is added. After washing away unbound biotinylated antibodies, HRP-conjugated streptavidin is pipetted to the wells. The wells are washed again, and a TMB substrate solution is added; color develops in proportion to the amount of Human CD16 and CD18 bound. The Stop Solution changes the color from blue to yellow, and the intensity is measured at 450 nm. Quantitative PCR (qPCR) Stool DNA was extracted with the QIAamp DNA Stool Mini Kit (Qiagen) with an initial bead-beating step. qPCR (SYBR Green) quantified Roseburia (Forward: 5’-TGATGCTGTTGAAAGGCAAC-3’; Reverse: 5’-CCTTACGGGTTTCCGTCAAT-3’) and Faecalibacterium (Forward: 5’-CCTACGGCAGCAGTAGGAA-3’; Reverse: 5’-GGTATGAAAGTTTCTGCGTGA-3’) against universal 16S rRNA (Forward: 5’-CACCACACCTTCTACAATGAG-3’; Reverse: 5’-TGGGTCAGAAGGATTCCTATG-3’). Each 20 µL reaction contained 2× Master Mix, 0.5 µM primers, and 2 µL diluted DNA (1:10). Thermocycling: 95°C for 10 min; 40 cycles of 95°C/15 s and 60°C/30 s; melt curve 60–95°C. Controls included no-template controls (NTC) and positive controls with known Roseburia faecalis/ Faecalibacterium prausnitzii DNA (10⁴ copies/µL); no reverse transcription was used. Absolute quantification used standard curves from plasmids (10²–10⁸ copies/µL); Ct values were converted to copy numbers. Normalization was performed as (i) copies per ng stool DNA and (ii) relative abundance (target copies / total bacterial 16S copies). LOD was determined empirically (Roseburia ≈ 10², Faecalibacterium ≈ 10², 16S ≈ 10¹ copies/reaction). Biomarker measurement The serum levels of Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) were measured using enzyme-linked immunosorbent assay (ELISA) kits (BioLegend, San Diego, USA) according to the manufacturer's instructions. The assays' sensitivity was verified, and all samples were run in duplicate to ensure accurate results. Statistical analysis All statistical analyses were conducted using SPSS Statistics software version 26.0 (SPSS Inc., Chicago, IL, USA). The normality of variables was assessed using the Shapiro-Wilk test. Subsequently, a one-way ANOVA followed by a post hoc Tukey test was conducted to compare group means. The correlation of variables was assessed using the Spearman correlation test, with statistical significance set at P < 0.05. The operating characteristic (ROC) curve and AUC were used to analyze the optimal cut-off for predicting positive RT-PCR cases. In this study, an AUC of 0.9 to 1 was defined as excellent accuracy, 0.8 to 0.9 as very good, 0.7 to 0.8 as good, 0.6 to 0.7 as sufficient, 0.5 to 0.6 as nasty, and < 0.5 as poor (useless test). Result Distinctive features of the examined cases A total of 90 subjects (48 males and 42 females) with a mean age of 56.34 ± 11.64years, including thirty patients in ICU (severe), thirty hospitalized patients (non-severe), and 30 controls (negative COVID-19) among those who were admitted to the Ayatollah Kashani Hospital (Tehran, Iran) enrolled in this case-control study. Pharyngeal swab specimens were collected from all participants for SARS-CoV-2 testing, and PCR (SANSURE Novel Coronavirus Nucleic Acid Diagnostic Kit) was performed to determine the presence of infection (inpatients) or its absence (in controls). The study protocol was approved by the Ethics Committee of Shahid Beheshti University of Medical Sciences (ethical code: IR.SBMU.RETECH.REC.1401.355). Serum CRP levels Figure 1 compares the CRP parameter between hospitalized and ICU patients with COVID-19 and control individuals. Serum CRP levels in ICU and hospitalized patients were significantly higher than in Control individuals (P < 0.01). Furthermore, CRP levels were significantly higher in ICU patients than in hospitalized patients (P < 0.01). Comparison of the CRP parameter among hospitalized and ICU patients with COVID-19 and control individuals .CRP values are presented as normalized values relative to the Control group (set as 1.0). The results are reported as the mean ± SD (n=3). * P < 0.05, ** P < 0.01, *** P < 0.001. Serum ALB levels Figure 2 compares the ALB parameter between hospitalized and ICU patients with COVID-19 and control individuals. Serum ALB levels in ICU patients (P < 0.001) and hospitalized patients were significantly higher than in Control individuals (P < 0.05). Furthermore, there was no significant difference in ALB levels between ICU patients and those who were hospitalized. Monitoring serum albumin levels can be a valuable tool for predicting and managing disease progression. Comparison of the Albumin parameter among hospitalized and ICU patients with COVID-19 and control individuals. Albumin values are presented as normalized values relative to the Control group (set as 1.0). The results are reported as the mean ± SD (n=3). * P < 0.05, *** P < 0.001. Serum ferritin activity Figure 3 compares the Ferritin parameter between hospitalized and ICU patients with COVID-19 and control individuals. Serum ferritin levels in ICU and hospitalized patients were significantly higher than in Control individuals (P < 0.01). Furthermore, there was no significant difference in ferritin levels between ICU and hospitalized patients. However, the ferritin-to-albumin ratio was significantly higher in ICU patients with COVID-19 than in Control individuals (Fig. 4, P < 0.05). The ferritin-to-albumin ratio holds promise as a potential indicator of COVID-19 mortality, with elevated levels correlating with an augmented risk of death. Comparison of the Ferritin parameter among hospitalized and ICU patients with COVID-19 and control individuals. Ferritin values are presented as normalized values relative to the Control group (set as 1.0) and results are reported as the mean ± SD (n=3). ** P < 0.01. Comparison of the ferritin-to-albumin ratio parameter among hospitalized and ICU patients with COVID-19 and control individuals. The results are reported as the mean ± SD (n=3). * P < 0.05. Serum NLRP3 levels Figure 5 compares the NLRP3 parameter between hospitalized and ICU patients with COVID-19 and control individuals. Serum NLRP3 levels in ICU and hospitalized patients were significantly higher than in control individuals (P < 0.001). Furthermore, there was no significant difference in NLRP3 levels between ICU and hospitalized patients. The NLRP3 inflammasome has been associated with COVID-19-related coagulopathy and immunothrombosis, leading to pathological thrombosis and multiorgan damage, such as atherosclerosis. Comparison of the NLRP3 parameter among hospitalized and ICU patients with COVID-19 and control individuals. NLRP3 values are presented as normalized values relative to the Control group (set as 1.0) and results are reported as the mean ± SD (n=3). *** P < 0.001 Serum CD16 and CD18 levels Figures 6A and 6B compare the CD16 and CD18 parameters between hospitalized and ICU patients with COVID-19 and control individuals. Serum levels of CD16 and CD18 in ICU and hospitalized patients were significantly higher than in Control individuals (P < 0.001). Furthermore, there was no significant difference in CD16 and CD18 levels between ICU patients and hospitalized patients. The ratio of CD18 to CD16 was significantly higher in ICU patients with COVID-19 than in control individuals (Fig. 6C). CD16 and CD18 play roles in the inflammatory response, the renin-angiotensin system, and endothelial dysfunction in the development of atherosclerosis in COVID-19 patients. Comparison of the A) CD16, B) CD18 and C) CD18 to CD16 ratio parameters among hospitalized and ICU patients with COVID-19 and control individuals. The results values are presented as normalized values relative to the Control group (set as 1.0) and reported as the mean ± SD (n=3). * P < 0.05, *** P < 0.001. Microbiome composition Quantitative PCR analysis revealed significant differences in the abundance of beneficial gut bacteria among participants. In ICU patients, the relative abundance of Roseburia was significantly reduced by 40% compared to healthy controls (p < 0.05). Similarly, Faecalibacterium levels were 35% lower in ICU patients than in general ward patients, indicating a pronounced dysbiosis in individuals with severe COVID-19 (Table 1). Table 1Relative abundance of microbiome taxa in ICU patients, general ward patients, and healthy controls (Mean ± SD). Significant differences in Roseburia and Faecalibacterium levels (p < 0.01 and p < 0.001, respectively) indicate lower abundances in ICU patients.Microbiome TaxaICU Patients (Mean ± SD)General Ward (Mean ± SD)Healthy Controls (Mean ± SD)p-valueRoseburia10.5% ± 4.218.3% ± 5.125.4% ± 3.8< 0.01Faecalibacterium5.4% ± 2.311.2% ± 3.720.1% ± 4.5< 0.001 Relative abundance of microbiome taxa in ICU patients, general ward patients, and healthy controls (Mean ± SD). Significant differences in Roseburia and Faecalibacterium levels (p < 0.01 and p < 0.001, respectively) indicate lower abundances in ICU patients. Cytokine levels Serum levels of Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α) were markedly elevated in severe COVID-19 cases compared to non-severe cases and healthy controls. The mean IL-6 levels in ICU patients were 50 ± 10 pg/mL, significantly higher than the 15 ± 3 pg/mL observed in general ward patients (p < 0.01) and the 10 ± 2 pg/mL observed in healthy controls (p < 0.001). Likewise, TNF-α levels were measured at 35 ± 6 pg/mL in ICU patients, compared to 10 ± 2 pg/mL in non-severe cases (p < 0.01) and 8 ± 1 pg/mL in controls (p < 0.001) (Table 2). Table 2Significantly elevated levels of both cytokines in ICU patients indicate a strong inflammatory response associated with severe COVID-19 cases compared to non-severe cases and healthy controls.GroupIL-6 (pg/mL) ± SDTNF-α (pg/mL) ± SDp-value (IL-6)p-value (TNF-α)Healthy Controls10 ± 28 ± 1--Non-Severe Cases15 ± 310 ± 2< 0.001< 0.01ICU Patients50 ± 1035 ± 6< 0.01< 0.01 Significantly elevated levels of both cytokines in ICU patients indicate a strong inflammatory response associated with severe COVID-19 cases compared to non-severe cases and healthy controls. Assessment of the sensitivities and specificities of variables Receiver operating characteristic (ROC) curves were utilized to predict the sensitivity and specificity of laboratory tests. The areas under the curves (AUCs) and associated p-values were as follows: CRP concentration (AUC = 0.899, p < 0.001), CD18 activity (AUC = 0.897, p < 0.001), CD16 activity (AUC = 0.873, p < 0.001), NLRP3 activity (AUC = 0.838, p < 0.001), FERR activity (AUC = 0.731, p < 0.001), ALB level (AUC = 0.707, p < 0.001), and CD18/CD16 ratio (AUC = 0.618, p = 0.07). Notably, CRP concentration, CD18, and CD16 levels exhibited the highest sensitivity and specificity among the variables (Figure 7). The ROC analysis of the studied parameters. The results proposed CRP, CD18 and CD16 as the best biomarkers for the susceptibility of COVID patients to atherosclerosis Discussion Atherosclerosis is a chronic inflammatory disease of medium-sized to large arteries, initiated and maintained by leukocyte infiltration into the subendothelial space. COVID-19 is a respiratory disease resulting from infection with the SARS-CoV-2 virus. COVID-19 can adversely affect the endothelium and cardiomyocytes, triggering blood clotting and the release of pro-inflammatory cytokines, thereby intensifying the development of atherosclerosis (12, 13). Approximately 25% of individuals with COVID-19 experience cardiovascular complications, especially among older individuals with pre-existing atherosclerosis and its associated clinical manifestations (14). In this study, we uncovered novel evidence that COVID-19 can exacerbate atherosclerosis. Atherosclerosis and COVID-19 may affect each other bidirectionally. The presence of cardiovascular disease can be influenced by an individual's susceptibility to viral infections. Numerous studies consistently demonstrate a substantial correlation between the severity of COVID-19 and the concentrations of C-reactive protein (CRP), Albumin, and Ferritin. Elevated levels of CRP have been associated with severe COVID-19 and poor prognosis (15). CRP is an acute-phase protein produced by the liver in response to inflammation in the body (16). Elevated levels of CRP have been observed in patients with COVID-19, especially those with severe disease (16, 18). In this study, we observed a significant increase in CRP levels among hospitalized and ICU patients with COVID-19 compared with Control individuals (Figure 1). A recent study found that CRP levels can be used as a diagnostic marker and also reflect the severity and prognosis of COVID-19. However, it is essential to note that there are numerous causes of elevated CRP, including acute and chronic responses, which can be infectious or non-infectious in etiology (16). Therefore, CRP alone cannot be used to diagnose COVID-19, but it can provide critical information for guiding clinical diagnosis and treatment of COVID-19-related uncontrolled inflammation (16, 18). Albumin is a protein produced by the liver and is essential for maintaining blood oncotic pressure (19). Numerous studies have demonstrated a correlation between diminished albumin levels and unfavorable outcomes in individuals with COVID-19, establishing it as a reliable predictor of both disease severity and mortality (19, 21). A study reported that 20% of non-surviving COVID-19 patients had elevated albumin levels (19). Albumin levels have also been found to be an independent risk factor for severe COVID-19 infection and death at 30 days (20). Elevated albumin levels are not commonly observed in COVID-19 patients, and they are not a predictor of disease severity or mortality (19, 21). In the current study, there is a noteworthy increase in albumin levels among hospitalized and ICU patients with COVID-19 compared with control individuals (Figure 2). Ferritin is a protein that stores and releases iron in response to the body's requirements. Increased ferritin levels have been observed in patients with COVID-19, especially in those with severe disease, in studies by Kurian SJ et al. and Id Z et al. Studies have shown that high ferritin levels are associated with a higher risk of complications and death in COVID-19 patients (17, 22). In this study, we observed a substantial increase in ferritin levels among hospitalized and ICU patients with COVID-19 compared with Control individuals (Figure 3). Ferritin levels can also serve as a diagnostic marker and reflect the severity and prognosis of COVID-19. A study found that individuals with severe or very severe COVID-19 had elevated serum ferritin levels, with the very severe group exhibiting significantly higher levels than the severe group (17). In another study, it was found that patients who succumbed to COVID-19 exhibited elevated ferritin levels upon hospital admission and consistently throughout their hospitalization. Hence, the study concluded that COVID-19 severity is closely associated with serum ferritin levels (17, 23). Furthermore, the ferritin-to-albumin ratio (FAR) has been proposed as a novel prognostic indicator for COVID-19, with higher levels associated with increased mortality risk (24, 25). In the current study, the ferritin-to-albumin ratio shows a significant increase among ICU patients with COVID-19 compared to the levels observed in Control individuals (Figure 4). This is consistent with the findings of Varım et al., who identified the neutrophil count to albumin ratio as a predictor of mortality in COVID-19 patients (26). Transcriptional changes in CD16 monocytes may contribute to the pathogenesis of COVID-19, with indications suggesting a potential role. In contrast, the significant involvement of the NLRP3 inflammasome in severe COVID-19 pathogenesis leads to systemic hyperinflammation and dysregulated cytokine release. Activating the NLRP3 inflammasome by SARS-CoV-2 infection intensifies cytokine production, further contributing to the cytokine storm observed in severe cases. Additionally, this activation is linked to endoplasmic reticulum (ER) stress, which has been found to contribute to atherosclerosis (27, 30). In the current study, a significant increase in NLRP3 levels was observed among both hospitalized and ICU patients with COVID-19 compared to Control individuals. Cytokine release is dependent on the isotype, with rat IgG2b and human IgG1 inducing the highest levels, a response inhibited by antibodies to CD16, the low-affinity Fc receptor for IgG (FcgammaR) (31). Peripheral blood CD16 monocytes are essential in the host response to viral infections, and COVID-19 is characterized by an altered immune and inflammatory response (27). Additionally, CD16 and CD18, two types of integrins, are involved in the recruitment of inflammatory cells in cardiovascular disease. CD18, also known as β2 integrin, is expressed on the surface of leukocytes. At the same time, CD16 is a low-affinity Fcγ receptor expressed on the surface of natural killer cells, monocytes, and macrophages (32, 33). In the present study, we observed a significant increase in CD16 and CD18 levels in both hospitalized and ICU patients with COVID-19 compared with control individuals (Figure 6A, B). Furthermore, the study revealed a significant increase in the CD18:CD16 ratio among ICU patients with COVID-19 compared to control individuals (Figure 6C). The accumulation of pro-inflammatory leukocytes drives the progression of atherosclerosis and its clinical complications, and directly modulates tissue-healing in the infarcted heart after myocardial infarction (34). CD18/CD16 is a pair of integrin receptors that play a crucial role in the recruitment of inflammatory cells in cardiovascular diseases, including atherosclerosis (35). The role of CD16 and CD18 in atherosclerosis is not yet fully understood (36). However, studies have shown that CD16 monocytes are associated with subclinical atherosclerosis. Additionally, CD18 has been shown to play a role in leukocyte localization during atherosclerosis (37). The relationship between atherosclerosis and COVID-19 is complex and multifaceted. Both conditions involve the renin-angiotensin system, with ACE2 playing a key role in SARS-CoV-2 infection and atherosclerosis (38). The conclusion that COVID-19 may exacerbate atherosclerosis by increasing CD16 and CD18 levels, as well as the higher sensitivity and specificity of serum CRP concentrations, CD18, and CD16 levels, strengthens this issue, potentially leading to adverse outcomes, and is supported by standard inflammatory mechanisms observed in both conditions. Compared to other variables, this suggests the potential for common treatment strategies. Further research and clinical validation are warranted to elucidate the precise mechanisms and clinical implications of these observed associations in the context of COVID-19. In this study, we aimed to investigate the gut microbiome's composition and its association with inflammatory markers in patients with severe COVID-19. Our results demonstrated significant dysbiosis characterized by reduced levels of beneficial bacteria, particularly Roseburia and Faecalibacterium, in ICU patients compared to those in the general ward and healthy controls. These findings align with previous research suggesting that a healthy gut microbiome is crucial for maintaining immune homeostasis and may play a protective role during infectious diseases. The substantial decrease in the abundance of Roseburia and Faecalibacterium in ICU patients could contribute to heightened systemic inflammation, as indicated by the elevated serum levels of Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α). Our correlation analysis further supports this notion, revealing a positive relationship between reductions in these beneficial taxa and increased cytokine levels. This suggests that dysbiosis may exacerbate inflammatory responses in critically ill patients, potentially worsening clinical outcomes. The significant differences observed in microbiome composition across groups underscore the importance of monitoring gut health in the context of COVID-19. Restoration of beneficial microbiota through dietary interventions or probiotic supplementation could represent a potential therapeutic strategy to mitigate inflammation and improve patient outcomes. Furthermore, receiver operating characteristic (ROC) analysis demonstrated excellent predictive validity for the studied biomarkers, reinforcing their potential utility in clinical settings for early identification of patients at risk of severe disease progression. Overall, our findings highlight the crucial role of the gut microbiome in modulating inflammatory responses during COVID-19 and suggest that therapeutic strategies targeting the microbiome could be beneficial in managing severe cases of the disease. Also, these findings can help provide a better understanding of COVID-19 and the factors that cause it, and offer researchers improved diagnostic methods for diseases associated with it. The findings presented underscore discernible differences in serum parameters among COVID-19 patients, particularly those in the ICU, compared with their control counterparts. Noteworthy variations were observed in key markers, including CRP, ALB, ferritin, NLRP3, CD16, and CD18, revealing distinctive patterns in both ICU and hospitalized patients. Elevated levels of NLRP3, CD16, and CD18 were notably elevated in both ICU and hospitalized patients, implicating their potential involvement in the inflammatory response, the renin-angiotensin system, and endothelial dysfunction. These findings suggest a potential role for CD16 and CD18 in the development of atherosclerosis in COVID-19 patients, adding a layer of complexity to our understanding of the disease's pathophysiology. It is also suggested that new therapeutic approaches can be developed by better understanding the factors involved in COVID-19, including atherosclerosis and its effects after infection, as well as the microbiome structure of infected individuals. Conflict of interests There is no conflict of interest for authors of this article. References